医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Healios K.K. Announces 3 Billion JPY (USD $30.6 Million) Capital Raise

2013年10月08日 PM10:25
このエントリーをはてなブックマークに追加


 

TOKYO

Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million). With completion of its capital campaign, which started in March 2013, Healios K.K. will continue development of promising new treatments for age-related macular degeneration (AMD) by hiPSC derived retinal pigment epithelium (RPE) cell transplantation under partnership with the following group of pioneering investors:

  • Dainippon Sumitomo Pharma Co., Ltd.
    (Headquarters: Osaka, Japan; President and CEO: Masayo Tada)
  • Nikon Corporation
    (Headquarters: Tokyo, Japan; President and CEO: Makoto Kimura)
  • Shin Nippon Biomedical Laboratories, Ltd.
    (Headquarters: Tokyo, Japan; President and CEO: Ryoichi Nagata)
  • Shibuya Kogyo Co., Ltd.
    (Headquarters: Ishikawa, Japan; President: Hirotoshi Shibuya)
  • Healios Investment Limited Partnership (Unlimited Liability Partner: DOGAN Investments, Inc.
    (Headquarters: Fukuoka, Japan; President and CEO: Daisuke Mori))
  • tella, Inc.
    (Headquarters: Tokyo, Japan; President and CEO: Yuichiro Yazaki)

Founded in February 24, 2011 Healios K.K. aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.
The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine.

About Healios K.K.

Company Name: Healios K.K. (formerly known as Retina Institute Japan K.K.)
Location: Tokyo, Japan
President and CEO: Hardy TS Kagimoto, M.D.
Founded: February 24, 2011
Stock Market: Unlisted

CONTACT

Healios K.K.
Hiroo Kitazawa, +81-3-3544-8730 (Office)
Corporate
Planning
h.kitazawa@healios.jp
Or
visit http://www.healios.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表